Exelixis, Inc. (EXEL) Director Sells $711,881.04 in Stock
Exelixis, Inc. (NASDAQ:EXEL) Director Carl B. Feldbaum sold 32,988 shares of Exelixis stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $21.58, for a total value of $711,881.04. Following the sale, the director now directly owns 52,721 shares in the company, valued at $1,137,719.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Exelixis, Inc. (NASDAQ:EXEL) traded down 0.65% on Tuesday, hitting $21.56. 3,584,471 shares of the stock were exchanged. The company has a market capitalization of $6.31 billion, a PE ratio of 1026.67 and a beta of 1.78. The company has a 50-day moving average price of $21.49 and a 200 day moving average price of $19.03. Exelixis, Inc. has a 1-year low of $5.14 and a 1-year high of $24.85.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Monday, May 1st. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.06. The firm had revenue of $80.90 million for the quarter, compared to analyst estimates of $65.23 million. The business’s revenue was up 425.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.27) EPS. Analysts anticipate that Exelixis, Inc. will post $0.18 EPS for the current fiscal year.
A number of research firms recently weighed in on EXEL. Needham & Company LLC began coverage on Exelixis in a research report on Friday, March 31st. They set a “buy” rating and a $28.00 target price on the stock. Oppenheimer Holdings Inc. reissued a “market perform” rating on shares of Exelixis in a research report on Friday, April 21st. Cann reissued a “hold” rating on shares of Exelixis in a research report on Wednesday, April 19th. Zacks Investment Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. Finally, CIBC initiated coverage on Exelixis in a research report on Thursday, March 16th. They set a “market perform” rating on the stock. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $18.37.
Several hedge funds have recently bought and sold shares of the company. Fortaleza Asset Management Inc. purchased a new stake in Exelixis during the first quarter valued at about $106,000. Pittenger & Anderson Inc. purchased a new stake in Exelixis during the fourth quarter valued at about $149,000. Commerzbank Aktiengesellschaft FI purchased a new stake in Exelixis during the fourth quarter valued at about $169,000. Meeder Asset Management Inc. purchased a new stake in Exelixis during the first quarter valued at about $170,000. Finally, Laurion Capital Management LP purchased a new stake in Exelixis during the third quarter valued at about $208,000. Institutional investors and hedge funds own 78.40% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.